Fig. 7

ECM depletion results in significant cell killing effects by RGD4C.AAVP-mediated HSVtk/GCV gene therapy. Cell viability of a) 9L rat gliosarcoma, b) SNB19 human glioblastoma, c) M21 human melanoma and d) U87 human glioblastoma measured after ECM treatment in conjunction with transduction by targeted RGD4C.AAVP or non-targeted NT.AAVP carrying the HSVtk transgene. The GCV (40 μM) was applied for 3 days and renewed daily starting 72 h after vector transduction. Cell killing was quantified by the trypan blue exclusion method and data expressed as percentage of control cells that were not treated with AAVP vectors. Data show the means of triplicate samples. A representative experiment is shown, and experiments were repeated three times with similar results. Statistics were performed by one way ANOVA with application of Tukey’s post-test, *, p < 0.05. Data are presented as mean ± s.e.m. Individual conditions were repeated in triplicates